Tests ketamine with midazolam for seizures in children before hospital arrival
Tests ketamine added to midazolam for prolonged seizures in children aged 2 to 16.
Key facts
- Who runs it
- Sohag University
- Where
- Sohag, EgyptSee the site
- Trial code
- Registry title
- Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 668 people, planned
- Started
- 3 Aug 2025
- Planned end
- 1 Aug 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ketamine
- Midazolam
- Record updated
- 5 August 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children aged 2 to 16 with long-standing epilepsy who have had a long convulsive seizure (status epilepticus) in the past year. It tests adding ketamine to a second dose of midazolam before reaching hospital.
- Age
- 2 to 16 years
- Sex
- All sexes can join
- Disease stage
- Epilepsy diagnosed at least 1 year ago, with at least 1 episode of convulsive status epilepticus in the past 12 months
Main reasons for not taking part
- Informed consent not obtained
- Known allergy or reason not to use ketamine
- Known reason not to have an injection into a muscle
- Another family member already in the same trial
- Later seizure events (only the first event counts)
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age from 2 to 16 years
- Established diagnosis of epilepsy of at least 1 year duration
- History of at least 1 episode of convulsive status epilepticus in the preceding 12 months
Who cannot take part
- Failure to obtain informed consent
- Known allergies or contraindications to ketamine
- Known contraindications to intramuscular injection
- Presence of another family member included in the same trial
- Having subsequent events (only the index event will be included)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 16 years old?
Where in Egypt
- Department of Pediatrics at Sohag University HospitalSohag, EgyptContact: Abdelrahim A Sadek, MD, PhDTaking people
About the trial
What the trial wants to find out
The goal of this pragmatic, decentralized, pre-consented, event-driven, randomized controlled trial is to investigate the efficacy of add-on ketamine to second-dose midazolam for prehospital treatment of epileptic children with convulsive status epilepticus.
The 2 groups in the trial
- Ketamine + MidazolamTreatment being tested
Treatment: Ketamine and Midazolam
- MidazolamExisting treatment, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Efficacy of Add-on Ketamine With Second-dose Midazolam for Prehospital Treatment of Epileptic Children With Status Epilepticus
- Plain-language title
- Tests ketamine with midazolam for seizures in children before hospital arrivalGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07095842, who can take part
- Record updated
- 5 August 2025